Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session.

In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks Consensus Estimates higher in just the past 7 days.

The company made the Zacks #1 Rank Top Performers List for Thursday with shares that are up approximately 4.4%. Volume is at 716,000 shares; above the daily average of 301,000.

Par Pharmaceutical develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets.

It is part of the Medical-Generic Drugs industry. There are 3 other names from this space on today’s Zacks #1 Rank List: Dr. Reddy’s Laboratories Ltd. (RDY), Hi-Tech Pharmacal Company, Inc. (HITK) and Impax Laboratories, Inc. (IPXL).

Earnings Estimates

For this year, the Zacks Consensus Estimate is at $1.93 per share, which is up 2.7% from $1.88 in 7 days and up 9.7% from $1.76 in 2 months.

Looking toward next year, the Zacks Consensus Estimate is pegged at $1.25, marking a 3.3% gain in the past week from $1.21. Furthermore, the guidance has advanced more than 20% in the past 60 days.

Recent Events

Par Pharmaceutical reported its second-quarter results on Aug 4. Since that time, some noteworthy events include:

• PRX receiving, on Sep 10, final approval from the FDA for nateglinide tablets; a generic version of Novartis’ Starlix. The tablets are to improve glycemic control in adults with Type II diabetes mellitus.
• PRX gaining approval, on Aug 18, from the FDA for a clonidine transdermal system, a generic version of the Catapres TTS high blood pressure patch. This is the first generic 7-day patch for the treatment of hypertension.
• On Aug 17, PRX announced that it won a patent dispute over the pain drug Ultram ER.

Second-Quarter Results

In early August, Par Pharmaceutical reported adjusted earnings per share of 65 cents on total revenues of $404 million for its second quarter.

The earnings result reversed a year-ago loss and also topped the Zacks Consensus Estimate by more than 35%. Meanwhile, revenue soared year over year from $112.9 million.

The big star of the quarter was Metoprolol, as net sales reached $306 million, up 173%. Metoprolol is the authorized generic version of AstraZeneca’s Toprol XL, a treatment for angina, high blood pressure and heart failure.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (GIII) Top Performer for Thurs: G-III Apparel- Zacks #1 Rank Top PerformersWe’re going to stick with the Textile-Apparel industry for a second consecutive day and feature...
2. (HITK) Top Performer for Wed: Hi-Tech Pharmacal- Zacks #1 Rank Top PerformersHi-Tech Pharmacal Co., Inc. (HITK) enjoyed a strong performance from generic pharmaceuticals in its fiscal...
3. (AZN) Almost 25 Pharmaceutical Companies are Racing to Bring H1N1the Vaccine to MarketAlthough we are waiting eagerly for the first H1N1 vaccine to hit the market, it...
4. (HELE) Top Performer for Thurs: Helen of Troy- Zacks #1 Rank Top PerformersHelen of Troy Ltd. (HELE) came out this morning with its fiscal first-quarter report, which...
5. (PRX) Par Pharmaceutical Companies, Inc. – Value – Zacks Rank BuyPar Pharmaceutical Companies, Inc. (PRX), the generic drug manufacturer, saw revenue grow 32% as sales...
6. (SCR) Simcere Pharmaceutical Group – Third Quarter Revenue Jumped 37.1%Simcere Pharmaceutical Group (SCR) saw revenues soar 37.1% as sales of generic pharmaceutical products stayed...

Search Posts by Tag: Dr. Reddy's Laboratories Limited | Hi Tech Pharmacal Company Inc | HITK | Impax Laboratories Inc | IPXL | Par Pharmaceutical Companies Inc | PRX | RDY | Drugs - Generic | Healthcare

RSS Feeds by Tag: Dr. Reddy's Laboratories Limited | Hi Tech Pharmacal Company Inc | HITK | Impax Laboratories Inc | IPXL | Par Pharmaceutical Companies Inc | PRX | RDY | Drugs - Generic | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author